Hepatitis B Vaccine Helps Prevent Liver Cancer
PHILADELPHIA—SmithKline Beecham has announced that labeling for Engerix-B (hepatitis B vaccine recombinant) now includes a statement recognizing the hepatitis B vaccine as “the first anti-cancer vaccine because it can prevent primary liver cancer. A clear link has been demonstrated between chronic hepatitis B infection and the occurrence of hepatocellular carcinoma.”
PHILADELPHIASmithKline Beecham has announced that labeling for Engerix-B (hepatitis B vaccine recombinant) now includes a statement recognizing the hepatitis B vaccine as the first anti-cancer vaccine because it can prevent primary liver cancer. A clear link has been demonstrated between chronic hepatitis B infection and the occurrence of hepatocellular carcinoma.
The labeling reflects the fact that the FDA has recognized the CDCs description of hepatitis B vaccines as preventing hepatitis B infections that can lead to primary liver cancer. In the United States, about 15% of the reported cases of primary liver cancer develop from chronic hepatitis B infections.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
